AUSTRALIA info@sudapharma.com
  • Facebook
  • Twitter
  • Linkedin
  • YouTube
+61 8 6142 5555
Dalcon Environmental
Menu
  • About Us
    • Snapshot
    • Our People
      • Leadership Team
      • Management Team
      • Scientific Advisory Board Members
    • Corporate Governance and Charters
  • Technology
  • Products
    • Zolpimist™ – Treatment for Insomnia
  • R&D
    • Anagrelide: Treatment for Cancer
    • Sumatriptan: Treatment for Migraine
    • Cannabinoids (CBD)
    • Ondansetron : Nausea
    • Sildenafil : Erectile Dysfunction/PAH
    • Midazolam: Treatment for Epilepsy & Anxiety
  • Investors
    • ASX Announcements
    • Presentations
    • Analyst Reports
    • Media
  • Contact Us

  • 29 Mar 21

    Newsletter March 2021

  • 07 Oct 20

    SUDA Newsletter Oct 2020

Recent

  • April 2021
  • March 2021

Archives

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • About Us
    • Snapshot
    • Our People
      • Leadership Team
      • Management Team
      • Scientific Advisory Board Members
    • Corporate Governance and Charters
  • Technology
  • Products
    • Zolpimist™ – Treatment for Insomnia
  • R&D
    • Anagrelide: Treatment for Cancer
    • Sumatriptan: Treatment for Migraine
    • Cannabinoids (CBD)
    • Ondansetron : Nausea
    • Sildenafil : Erectile Dysfunction/PAH
    • Midazolam: Treatment for Epilepsy & Anxiety
  • Investors
    • ASX Announcements
    • Presentations
    • Analyst Reports
    • Media
  • Contact Us

Shareholder Email Alerts

    SUDA Pharma Logo White

    P: +61 8 6142 5555
    Level 1, Unit 12, 55 Howe Street, Osborne Park, Western Australia 6017
    PO Box 1719, Osborne Park BC, Western Australia 6916

    Copyright 2019 ACN 090 987 250 | ALL RIGHTS RESERVED

    Website by Indepth
    Animation video developed by www.JonHuhn.com